CNTX Stock Forecast: Context Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.16
−5.33% on the day

The median 12-month analyst price target for Context Therapeutics, Inc. is $5. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 38 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$14.7M
Ticker Nerd rank
38/ 100
Median analyst target
$5.00
Analysts covering
10
Revenue$0.0
Operating income−$15.0M
Net income−$14.6M
Free cash flow−$11.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−11.6%
1M
−34.4%
YTD
−89.1%
1Y
−86.0%
From 52W high
−95.2%
From 52W low
0.0%
$0.16
$3.36
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Context Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
38/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
71
Accruals
66
Revisions
62
Quality
48
Issuance
40
Value
32
Growth
11
Momentum
7

Volatility (71): The share price has been relatively steady.

Momentum (7): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

CNTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CNTX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$1.00$2.00$3.00$4.00$5.00Jan 26Apr 26Jul 26Oct 26CNTXHigh $5.00Median $5.00Low $1.50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says10 analysts
9
Buy
1
Hold
0
Sell
$1.50
Low
$5.00
Median
$5.00
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
16 June 2026Maxim GroupMaintainsBuy$8.00 → $4.00
24 Mar 2026D. Boral CapitalMaintainsBuy—
24 Mar 2026GuggenheimReiteratesBuy—
24 Mar 2026Piper SandlerMaintainsOverweight—
22 Dec 2025Jones TradingInitiatesBuy—
6 Nov 2025D. Boral CapitalMaintainsBuy—
6 Nov 2025HC Wainwright & Co.MaintainsBuy—
16 Oct 2025D. Boral CapitalMaintainsBuy—
2 Oct 2025Cantor FitzgeraldInitiatesOverweight—
18 Sept 2025GuggenheimInitiatesBuy—
7 Aug 2025D. Boral CapitalMaintainsBuy—
7 Aug 2025HC Wainwright & Co.MaintainsBuy—
26 June 2025Piper SandlerReiteratesOverweight—
8 May 2025D. Boral CapitalMaintainsBuy—
29 Apr 2025D. Boral CapitalMaintainsBuy—
21 Apr 2025William BlairInitiatesOutperform—
9 Apr 2025D. Boral CapitalMaintainsBuy—
21 Mar 2025D. Boral CapitalMaintainsBuy—
21 Mar 2025HC Wainwright & Co.ReiteratesBuy—
15 Jan 2025D. Boral CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for CNTX.

Market Radar

This page is one stock. Monday covers all of them.

CNTX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

CNTX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Context Therapeutics, Inc. returned −86.0% against +6.9% for the S&P 500, dividends included.

CNTX vs S&P 500, last 12 monthsTotal return, rebased to 100
−50050100150200250300Jan 26Apr 26Jul 26Oct 26CNTXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CNTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
6
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
0.5×

Cheaper than 87% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−84.3%

Higher than 15% of US stocks

Return on assets
−49.8%

Higher than 8% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Context Therapeutics, Inc. has a market value of $14.7M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$46.0M.

  • Free cash flow in the twelve months to 30 June 2026: −$40.5M.

  • Shares outstanding: 91.9M.

  • Context Therapeutics, Inc. employs 15 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

CNTX and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CNTXContext Therapeutics, Inc.$14.7M38
CELUCelularity, Inc.$15.0M29
CTXRCitius Pharmaceuticals, Inc.$14.0M34
PBMPsyence Biomedical Ltd.$15.8M4
BYSIBeyondSpring, Inc.$13.7M11
ACTUActuate Therapeutics, Inc.$13.6M39
ATOSAtossa Therapeutics, Inc.$15.9M22

Take a look at CNTX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Context Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about CNTX

What is the CNTX stock price forecast for 2026-2027?

The median 12-month analyst price target for Context Therapeutics, Inc. is $5, with estimates ranging from $1.5 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CNTX stock a buy right now?

Of the 10 analysts covering Context Therapeutics, Inc., 9 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Context Therapeutics, Inc. 38 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CNTX?

As at 21 Nov 2026, Context Therapeutics, Inc. ranks 38 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (71 of 100).

Will CNTX stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts is $5, and Ticker Nerd's factor model ranks Context Therapeutics, Inc. 38 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CNTX stock forecast for 2030?

No analyst covering Context Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CNTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.5 to $5 over the next 12 months.

How has CNTX stock performed over the past year?

Context Therapeutics, Inc. returned -86.0% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Context Therapeutics, Inc. do?

Context Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for solid tumors, with an emphasis on hormone-driven breast and gynecological cancers. Its current pipeline centers on T cell engaging bispecific antibodies designed to direct immune activity toward cancer cells, including programs targeting CLDN6, mesothelin, and Nectin-4.

Company

About Context Therapeutics, Inc.

Context Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for solid tumors, with an emphasis on hormone-driven breast and gynecological cancers. Its current pipeline centers on T cell engaging bispecific antibodies designed to direct immune activity toward cancer cells, including programs targeting CLDN6, mesothelin, and Nectin-4. The company is advancing these candidates through early-stage clinical and preclinical development, with particular attention to cancers such as ovarian, endometrial, and breast cancer. Context Therapeutics Inc. operates as an oncology-focused biotechnology company and works to translate targeted immunotherapy research into potential treatments for genetically and biologically defined patient populations. Headquartered in Philadelphia, Pennsylvania, it remains centered on drug discovery and clinical development rather than commercialized products.

CEO Mr. Martin A. Lehr · 15 employees · United States · https://www.contexttherapeutics.com